Learning From Success and Failure: Biologics for Non-Approved Skin Diseases

    August 2019 in “ Frontiers in immunology ”
    Reinhart Speeckaert, Debabrata Bandyopadhyay, Nanja van Geel
    Studysummary This review discusses the potential of biologics for treating various skin disorders, highlighting positive outcomes in conditions like pityriasis rubra pilaris and lupus, while noting mixed efficacy in others like alopecia areata; it reports no new clinical results.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Read the full study on frontiersin.org →
    Discuss this study in the Community →

    Research cited in this study 7

    1. Response to Ustekinumab in Three Pediatric Patients with Alopecia Areata Pediatric dermatology · 2018
    2. Alopecia Universalis Under Adalimumab Therapy in a Patient with Rheumatoid Arthritis Zeitschrift für Rheumatologie · 2018
    3. Effective Use of Ustekinumab in a Patient with Concomitant Psoriasis, Vitiligo, and Alopecia Areata JAAD case reports · 2017
    4. Adalimumab-Related Alopecia in a Patient Affected by Psoriasis Dermatology Online Journal · 2017
    5. Extensive Alopecia Areata Is Reversed by IL-12/IL-23p40 Cytokine Antagonism The Journal of Allergy and Clinical Immunology · 2015
    6. Alopecia Universalis Successfully Treated With Adalimumab JAMA dermatology · 2014
    7. Safety and Efficacy of Adalimumab for the Treatment of Severe Alopecia Areata: Case Series of Three Patients Journal of cutaneous medicine and surgery · 2012